



Low-Dose, Long-Term Drug Exposure and Epigenetic Changes: Rethinking Drug Evaluation Models

Dr. Sanket Satish Mohata

Assistant Professor, Department of Dravyaguna Vigyan

Bhausaheb Mulak Ayurved Mahavidyalaya, Nandanwan, Nagpur, Maharashtra, India

Abstract

Introduction: *Ayurvedic* pharmacology, particularly the discipline of *Dravyaguna*, emphasizes **repeated administration of low doses over prolonged durations** to achieve stable and sustained therapeutic effects. Such effects are frequently delayed in onset and persist beyond the period of drug administration. However, conventional drug evaluation models, which prioritize high-dose, short-term therapeutic responses, fail to adequately explain these observations.

Methods: A conceptual narrative review was conducted focusing on ***Ayurvedic* pharmacological principles related to dosage, repetition, and duration**, as discussed in contemporary *Ayurveda* and integrative medicine literature. These principles were examined in light of current biomedical research on **epigenetic regulatory mechanisms** to explore a scientific basis for sustained therapeutic effects associated with repeated low-dose, long-term drug exposure.

Results: *Ayurvedic* pharmacological concepts consistently describe drug action as a **gradual biological process leading to long-term functional adaptation**, rather than immediate pharmacodynamic effects. Modern epigenetic mechanisms including DNA methylation, histone modifications, and non-coding RNA regulation provide a plausible explanation for these observations by enabling stable modulation of gene expression without altering the DNA sequence.

Discussion: Current drug evaluation frameworks may inadequately capture therapeutic effects emphasized in *Ayurveda*, as they are optimized for short-term and high-dose interventions. Epigenetic science offers a contemporary explanatory framework that supports *Ayurvedic* pharmacological principles and highlights the need to reconsider existing drug evaluation models to better assess sustained therapeutic effects.

Keywords: Repeated low-dose exposure; Long-term drug administration; Epigenetic changes; *Ayurvedic* pharmacology

Introduction

Contemporary drug evaluation models are predominantly structured to assess the effects of **high-dose, short-term therapeutic exposure**, with an emphasis on rapid symptom control and immediately measurable biochemical outcomes¹. While this approach is effective for acute conditions, it remains insufficient for explaining therapeutic responses that develop **gradually over prolonged durations** and persist even after discontinuation of treatment².

In *Ayurvedic* pharmacology, drug action is traditionally understood as a **time-dependent and cumulative biological process**, particularly when drugs are administered repeatedly in low doses over extended periods. Such therapeutic regimens are widely employed in chronic and preventive contexts, where benefits often emerge slowly and remain stable³. However, these sustained effects are frequently underestimated or overlooked when evaluated using conventional dose–response paradigms that prioritize dose intensity over exposure pattern and duration⁴.

Recent advances in epigenetic research provide a biologically plausible explanation for these *Ayurvedic* observations. Epigenetic mechanisms regulate gene expression without altering the DNA sequence and enable cells to adapt to repeated external signals, creating a form of **biological memory**^{5, 6}. This article examines how epigenetic changes may underlie the sustained therapeutic effects emphasized in *Ayurvedic* pharmacology and critically analyses the limitations of current drug evaluation models in capturing such adaptations.

Concept of Repeated Low-Dose, Long-Term Therapeutic Exposure in *Ayurvedic* Pharmacology

Ayurvedic pharmacology, as articulated in *Dravyaguna*, conceptualizes drug action as a **gradual process of biological normalization** rather than immediate symptom suppression. Repeated administration of low doses over long durations is intentionally employed to promote stable physiological adaptation and long-term functional balance⁷.

Unlike conventional pharmacological strategies that often rely on maximal dosing to achieve rapid effects, *Ayurvedic* therapeutic regimens emphasize **consistency, repetition, and duration**. This approach allows continuous biological signalling while minimizing adverse effects, thereby facilitating progressive modulation of regulatory pathways⁸.

Such exposure patterns are particularly relevant in chronic disease management and preventive healthcare, where therapeutic success is measured not by immediate outcomes but by sustained improvement over time. From this perspective, drug efficacy is understood as an **adaptive biological response**, shaped by cumulative exposure rather than a linear dose-dependent effect⁹.

Epigenetic Changes and Biological Memory

Epigenetic changes are stable yet reversible modifications that influence gene expression **without altering the underlying DNA sequence**¹⁰. These changes play a fundamental role in development, differentiation, and long-term cellular adaptation¹¹. The principal epigenetic mechanisms include **DNA methylation, histone modifications**, and **non-coding RNA regulation**¹².

DNA methylation is commonly associated with long-term transcriptional regulation¹³, while histone modifications alter chromatin structure and transcriptional accessibility¹⁴. Non-coding RNAs, particularly microRNAs, further regulate gene expression by influencing mRNA stability and translation¹⁵.

A defining feature of epigenetic regulation is its capacity to generate **biological memory**. Repeated or sustained exposure to a stimulus can establish persistent epigenetic marks that remain even after the stimulus is withdrawn¹⁶. In the context of repeated low-dose, long-term drug exposure, such mechanisms provide a credible explanation for delayed yet sustained therapeutic effects that are not detectable in short-duration studies¹⁷.

Ayurvedic Interpretation of Sustained Drug Action Through Epigenetic Adaptation

Ayurvedic pharmacology has long recognized that therapeutic effects may **manifest gradually and persist beyond the period of drug administration**. This observation reflects an understanding that drug action influences deeper regulatory mechanisms rather than producing transient effects alone. Contemporary *Ayurveda* scholarship describes these sustained outcomes as the result of long-term biological adaptation rather than immediate pharmacodynamic impact¹⁸.

Modern integrative medicine research suggests that such *Ayurvedic* observations align closely with epigenetic principles. Repeated low-intensity therapeutic signals can progressively reprogram gene expression patterns, leading to stable functional changes at the cellular and systemic levels¹⁹. Epigenetic reprogramming thus provides a scientific framework for interpreting the sustained therapeutic effects emphasized in *Ayurvedic* pharmacology.

Importantly, epigenetics does not replace *Ayurvedic* theory but **offers a mechanistic explanation** for pharmacological principles derived from long-standing clinical observation and experiential knowledge. In this way, epigenetic science strengthens the contemporary scientific interpretation of *Ayurvedic* drug action without altering its foundational concepts²⁰.

Limitations of Current Drug Evaluation Models

Current drug evaluation models are optimized to detect **acute, reversible effects**, typically using high-dose administration over limited durations⁷. These models assume that therapeutic effects diminish following drug withdrawal, an assumption that does not account for stable molecular adaptations mediated through epigenetic mechanisms⁶.

Conventional dose–response frameworks emphasize dose magnitude while underestimating the role of exposure frequency and duration⁴. As a result, therapies operating through gradual biological reprogramming may appear pharmacologically weak or ineffective when evaluated using standard endpoints⁸.

Furthermore, routine evaluation protocols rely heavily on phenotypic and symptomatic outcomes, rarely incorporating **molecular or epigenetic markers** that may precede or outlast observable clinical effects^{21, 22}. This methodological limitation restricts the ability of current models to recognize epigenetically mediated adaptations induced by repeated low-dose exposure.

Implications for Future Pharmacological Research

Recognition of epigenetic changes as mediators of sustained therapeutic effects necessitates a reorientation of pharmacological research frameworks²³. Longer study durations and longitudinal designs are required to detect delayed molecular adaptations¹⁶.

Incorporation of epigenetic endpoints such as DNA methylation profiles or chromatin modifications may enhance mechanistic understanding and improve evaluation sensitivity²⁴. Reassessing dose–time relationships, rather than focusing exclusively on maximal dose or peak concentration, may allow more accurate interpretation of therapies based on cumulative biological signalling^{4, 8}.

Conclusion

Repeated low-dose, long-term drug exposure represents a therapeutic paradigm central to *Ayurvedic* pharmacology and increasingly relevant to modern biomedical science. Epigenetic changes provide a biologically plausible mechanism for understanding delayed yet sustained therapeutic effects long emphasized in *Dravyaguna*. Integrating epigenetic perspectives into drug evaluation frameworks may improve recognition of long-term therapeutic adaptations and strengthen the scientific interpretation of *Ayurvedic* pharmacological principles.

References

1. Gabrielsson J, Weiner D. *Pharmacokinetic and pharmacodynamic data analysis: concepts and applications*. 5th ed. Boca Raton: CRC Press; 2016.
2. Turner JR. The translational gap in drug development. *Nat Rev Drug Discov*. 2019;18(10):747-748.
3. Patwardhan B, Mashelkar RA. Traditional medicine-inspired approaches to drug discovery. *Drug Discov Today*. 2009;14(15-16):804-811.
4. Calabrese EJ. Hormetic mechanisms. *Crit Rev Toxicol*. 2013;43(7):580-606.
5. Bird A. Perceptions of epigenetics. *Nature*. 2007;447(7143):396-398.
6. Allis CD, Jenuwein T. The molecular hallmarks of epigenetic control. *Nat Rev Genet*. 2016;17(8):487-500.

7. Rang HP, Ritter JM, Flower RJ, Henderson G. *Rang and Dale's pharmacology*. 9th ed. London: Elsevier; 2020.
8. Calabrese EJ, Mattson MP. Hormesis provides a quantitative estimate of biological plasticity. *Crit Rev Toxicol*. 2017;47(4):332-343.
9. Waddington CH. The epigenotype. *Int J Epidemiol*. 2012;41(1):10-13.
10. Goldberg AD, Allis CD, Bernstein E. Epigenetics: a landscape takes shape. *Cell*. 2007;128(4):635-638.
11. Jones PA, Takai D. DNA methylation in mammalian epigenetics. *Science*. 2001;293(5532):1068-1070.
12. Bannister AJ, Kouzarides T. Chromatin regulation by histone modifications. *Cell Res*. 2011;21(3):381-395.
13. Bartel DP. MicroRNAs: mechanism and function. *Cell*. 2004;116(2):281-297.
14. Feil R, Fraga MF. Epigenetics and the environment. *Nat Rev Genet*. 2012;13(2):97-109.
15. D'Urso A, Brickner JH. Epigenetic transcriptional memory. *Curr Genet*. 2014;60(2):89-100.
16. Cavalli G, Heard E. Genetics and the environment. *Nature*. 2019;571(7766):489-499.
17. Feinberg AP. Epigenetics at the epicenter of modern medicine. *JAMA*. 2008;299(11):1345-1350.
18. Tilburt JC, Kaptchuk TJ. Herbal medicine research and global health. *BMJ*. 2008;337: a2813.
19. Efferth T, Kaina B. Epigenetic regulation by natural products. *Biotechnol Adv*. 2011;29(3):327-338.
20. Patwardhan B. *Ayurveda* and epigenetics. *J Ayurveda Integr Med*. 2014;5(4):209-210.
21. Skinner MK. Environmental epigenetics. *EMBO Rep*. 2011;12(7):620-622.
22. Lappalainen T, Grealley JM. Epigenetic variation and human phenotypes. *Nat Rev Genet*. 2017;18(7):441-451.
23. Ioannidis JPA. Why most true associations are inflated. *Epidemiology*. 2008;19(5):640-648.
24. Michels KB. Epigenetic epidemiology. *Curr Epidemiol Rep*. 2014;1(1):1-8.